Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 63

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 63
---
 have on the consolidated financial statements.

107

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)2. Summary of Significant Accounting Policies (Continued)

SEC Final Climate Rule

In March 2024, the U.S. Securities and Exchange Commission (SEC) adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors (Final Rule). This rule will require registrants to disclose certain climate-related information in registration statements and annual reports with staggered compliance dates for large accelerated filers for the various aspects of the Final Rule. On April 4, 2024, the SEC issued an order staying the Final Rule. The SEC’s administrative stay is expected to remain in place until the completion of litigation filed in various federal courts challenging, among other things, the agency’s authority to adopt the Final Rule. The Company is evaluating the final rule to determine its impact on the Company's disclosures. 

3. Disaggregated Revenues

The following table provides information regarding total revenues (dollars in thousands): Year Ended December 31, 202420232022Net product sales   Qelbree$241,273 $140,192 $61,322 GOCOVRI130,824 119,637 104,421 Oxtellar XR99,464 113,404 115,345 APOKYN73,926 75,083 75,305 Trokendi XR63,201 94,336 261,221 Other(1)29,008 31,281 31,818 Total net product sales637,696 573,933 649,432 Royalty, licensing and other revenues24,121 33,588 17,806 Total revenues$661,817 $607,521 $667,238 ______________________________(1)   Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.In December 2023, the Company submitted to the FDA a notification of discontinuance to withdraw Osmolex ER from distribution. Distribution of Osmolex ER ceased on April 1, 2024.The Company recognized noncash royalty revenues of $4.0 million, and $9.8 million for the years ended December 31, 2023 and 2022, respectively. The Company no longer recognizes noncash royalty revenue as ownership